Stock BMRN BIOMARIN PHARMACEUTICAL INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-17 pm EDT 		5-day change 1st Jan Change
90.47 USD -0.44% Intraday chart for BioMarin Pharmaceutical Inc. +0.29% -6.17%
Apr. 15 Biomarin Pharmaceutical Insider Sold Shares Worth $3,645,000, According to a Recent SEC Filing MT
Apr. 01 Biomarin Pharmaceutical Insider Sold Shares Worth $2,173,341, According to a Recent SEC Filing MT

Business Summary

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

Number of employees: 3,401

Sales per Business

USD in Million2022Weight2023Weight Delta
Innovative Therapies
100.0 %
2,096 100.0 % 2,419 100.0 % +15.42%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
31.9 %
684 32.6 % 771 31.9 % +12.72%
Europe
27.7 %
651 31.1 % 669 27.7 % +2.82%
Rest of World
19.4 %
312 14.9 % 468 19.4 % +50.28%
Latin America
13.7 %
267 12.7 % 332 13.7 % +24.60%
Global
7.4 %
182 8.7 % 178 7.4 % -2.47%

Managers

Managers TitleAgeSince
Alexander Hardy CEO
 Chief Executive Officer 56 Nov. 30
Brian Mueller DFI
 Director of Finance/CFO 50 02-11-30
Kevin Eggan CTO
 Chief Tech/Sci/R&D Officer - 20-10-04
Philip Lo Scalzo CMP
 Compliance Officer - 06-12-31
Eduardo Von Pervieux CTO
 Chief Tech/Sci/R&D Officer - 08-10-31
C. Guyer CTO
 Chief Tech/Sci/R&D Officer 62 -
Stuart Bunting CTO
 Chief Tech/Sci/R&D Officer - 08-10-31
Henry Fuchs CTO
 Chief Tech/Sci/R&D Officer 66 09-02-28
Jean-Jacques Bienaimé BRD
 Director/Board Member 70 05-05-15
Traci McCarty IRC
 Investor Relations Contact - -

Members of the board

Members of the board TitleAgeSince
David Pyott BRD
 Director/Board Member 70 16-01-03
Jean-Jacques Bienaimé BRD
 Director/Board Member 70 05-05-15
Randy Meier CHM
 Chairman 65 06-12-13
Elaine Heron BRD
 Director/Board Member 76 02-06-30
V. Lawlis BRD
 Director/Board Member 72 07-05-31
May Kin Ho BRD
 Director/Board Member 71 21-02-16
Mark Enyedy BRD
 Director/Board Member 60 Dec. 26
Robert Hombach BRD
 Director/Board Member 58 17-09-28
Willard Dere BRD
 Director/Board Member 70 16-07-17
Elizabeth Anderson BRD
 Director/Board Member 66 19-07-09

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 189,775,040 188,177,949 ( 99.16 %) 0 99.16 %

Shareholders

NameEquities%Valuation
PRIMECAP Management Co.
9.760 %
18,414,374 9.760 % 1 608 M $
Vanguard Fiduciary Trust Co.
9.567 %
18,050,062 9.567 % 1 576 M $
Dodge & Cox
7.417 %
13,994,063 7.417 % 1 222 M $
BlackRock Advisors LLC
6.487 %
12,239,423 6.487 % 1 069 M $
Capital Research & Management Co. (Global Investors)
5.711 %
10,774,641 5.711 % 941 M $
STATE STREET CORPORATION
3.567 %
6,730,515 3.567 % 588 M $
Ameriprise Trust Co.
2.872 %
5,419,366 2.872 % 473 M $
Barclays Bank Plc
2.803 %
5,288,893 2.803 % 462 M $
Viking Global Investors LP
2.591 %
4,889,454 2.591 % 427 M $
Avoro Capital Advisor LLC
2.279 %
4,300,000 2.279 % 376 M $

Company contact information

BioMarin Pharmaceutical, Inc.

770 Lindaro Street

94901, San Rafael

+415 506 6700

http://www.biomarin.com
address BioMarin Pharmaceutical Inc.(BMRN)

Group companies

NameCategory and Sector
BioMarin International Ltd.
Logo BioMarin International Ltd.

BioMarin International Ltd.

BiotechnologyHealth Technology

BioMarin International develops and commercializes biopharmaceuticals. The company was founded on June 16, 2011 and is headquartered in Dublin, Ireland.

Biotechnology

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per region

Ratings for BioMarin Pharmaceutical Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
90.87 USD
Average target price
110 USD
Spread / Average Target
+21.08%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-6.17% 17.24B
CSL LIMITED Stock CSL Limited
-4.89% 85.08B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.11% 40.14B
BIOGEN INC. Stock Biogen Inc.
-25.74% 28.37B
UCB Stock UCB
+51.96% 24.07B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-31.09% 13.85B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-6.58% 12.29B
INCYTE CORPORATION Stock Incyte Corporation
-16.04% 11.95B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
-4.19% 8.02B
INTRA-CELLULAR THERAPIES, INC. Stock Intra-Cellular Therapies, Inc.
+7.08% 7.73B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. BMRN Stock
  4. Company BioMarin Pharmaceutical Inc.